171 related articles for article (PubMed ID: 16192585)
1. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
Zia MI; Siu LL; Pond GR; Chen EX
J Clin Oncol; 2005 Oct; 23(28):6982-91. PubMed ID: 16192585
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical trials of biotherapies in solid tumors: a 5-year survey.
Ottaiano A; Mollo E; Di Lorenzo G; Pisano C; Di Maio M; Barletta E; Pensabene M; Segati R; Bullian P; Nasti G; Bryce J; Scala S; Castello G; Ascierto PA
Cancer Immunol Immunother; 2005 Jan; 54(1):44-50. PubMed ID: 15693138
[TBL] [Abstract][Full Text] [Related]
3. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
4. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
Mazumdar M; Fazzari M; Panageas KS
Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
Mooney MM; Schoenfeldt M
Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
[No Abstract] [Full Text] [Related]
6. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
[TBL] [Abstract][Full Text] [Related]
8. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
10. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
11. [Non-small cell lung cancer (NSCLC): the evolution of neo-adjuvant chemotherapy in the last 15 years].
Santo A; Genestreti G; Fiorio E; Terzi A; Lonardoni A; Calabrò F; Campaldini B; Colaluca P; Molino A; Cetto GL
Recenti Prog Med; 2006 Apr; 97(4):211-8. PubMed ID: 16729492
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language.
Glynne-Jones R; Mawdsley S; Novell JR
Colorectal Dis; 2006 Nov; 8(9):800-7. PubMed ID: 17032329
[TBL] [Abstract][Full Text] [Related]
13. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
17. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
19. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
[TBL] [Abstract][Full Text] [Related]
20. Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting.
Liang F; Wu Z; Mo M; Zhou C; Shen J; Wang Z; Zheng Y
Eur J Cancer; 2019 Nov; 121():19-28. PubMed ID: 31526874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
